Petros Pharmaceuticals, Inc. Impairment of Intangible Assets, Finite-lived
Petros Pharmaceuticals, Inc. (PTPI) reported Impairment of Intangible Assets, Finite-lived of $2.97 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2025-03-31
- Petros Pharmaceuticals, Inc. impairment of intangible assets, finite-lived for the quarter ending 2022-12-31 was $0.00.
- Petros Pharmaceuticals, Inc. impairment of intangible assets, finite-lived for the quarter ending 2022-09-30 was $7.46M.
- Petros Pharmaceuticals, Inc. impairment of intangible assets, finite-lived for fiscal 2024 was $2.97M.
- Petros Pharmaceuticals, Inc. impairment of intangible assets, finite-lived for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Petros Pharmaceuticals, Inc. impairment of intangible assets, finite-lived for fiscal 2022 was $7.46M.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2024-12-31 | $2.97M 10-K · filed 2025-03-31 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $7.46M derived: sum of 2 quarters · filed 2024-04-01 | $7.46M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $7.46M 10-Q · filed 2023-11-15 | $7.46M 10-Q · filed 2023-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |